NasdaqGM - Nasdaq Real Time Price USD

Foghorn Therapeutics Inc. (FHTX)

4.2000

-0.3300

(-7.28%)

At close: May 9 at 4:00:00 PM EDT

4.4100

+0.21

+(5.00%)

After hours: May 9 at 5:01:31 PM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for FHTX

Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development

Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

PRLD Prelude Therapeutics Incorporated

0.7810

-4.49%

CGEM Cullinan Therapeutics, Inc.

7.54

-2.96%

STTK Shattuck Labs, Inc.

0.9479

+0.88%

SLDB Solid Biosciences Inc.

2.7600

-0.36%

KYMR Kymera Therapeutics, Inc.

30.07

-2.27%

CCCC C4 Therapeutics, Inc.

1.4700

-4.55%

NRIX Nurix Therapeutics, Inc.

9.50

-1.45%

STOK Stoke Therapeutics, Inc.

9.36

+3.43%

EWTX Edgewise Therapeutics, Inc.

14.58

-0.82%

ANRO Alto Neuroscience, Inc.

2.2200

+1.37%